Last updated: September 8, 2026
Amlodipine besylate and atorvastatin calcium are mature, low-cost generic medicines used for hypertension, angina, and dyslipidemia. The fixed-dose combination was commercialized by Pfizer as Caduet. Its U.S. composition patent protection has expired, FDA exclusivity has ended, and generic competition has materially reduced branded pricing power. Current value is concentrated in manufacturing scale, pharmacy access, supply reliability, and combination-product positioning rather than intellectual-property exclusivity.
What are amlodipine besylate and atorvastatin calcium used for?
Amlodipine is a dihydropyridine calcium-channel blocker. It lowers blood pressure and treats chronic stable or vasospastic angina.
Atorvastatin is an HMG-CoA reductase inhibitor used to reduce low-density lipoprotein cholesterol and cardiovascular risk.
Caduet combines both active ingredients in a single tablet. FDA-approved strengths include:
| Amlodipine dose |
Atorvastatin dose |
| 2.5 mg |
10 mg, 20 mg, 40 mg, 80 mg |
| 5 mg |
10 mg, 20 mg, 40 mg, 80 mg |
| 10 mg |
10 mg, 20 mg, 40 mg, 80 mg |
The combination is intended for patients who require treatment for hypertension or angina and lipid lowering. It does not represent a new molecular entity. The commercial rationale is adherence improvement and pill burden reduction.
What is the FDA and Orange Book status of Caduet?
Caduet was approved by the FDA in 2004 under NDA 021540. Pfizer is the original sponsor and commercial innovator. The product is listed in the FDA Orange Book as a prescription combination drug with amlodipine besylate and atorvastatin calcium as its active ingredients (U.S. Food and Drug Administration, n.d.-a).
The product’s regulatory exclusivity is no longer active.
| Regulatory item |
Status |
| Original product |
Caduet |
| Original sponsor |
Pfizer |
| NDA |
021540 |
| Approval year |
2004 |
| Dosage form |
Immediate-release tablet |
| Active ingredients |
Amlodipine besylate and atorvastatin calcium |
| FDA exclusivity |
Expired |
| Orange Book patent protection |
Expired |
| Biosimilar pathway |
Not applicable |
The product is a small-molecule drug. Generic applicants use the abbreviated new drug application, or ANDA, pathway. Biosimilar competition does not apply because neither active ingredient is a biologic.
What patents protect amlodipine besylate and atorvastatin calcium?
The principal patent estate for Caduet was directed to the combination of amlodipine and atorvastatin rather than to currently enforceable protection for the individual active ingredients.
Pfizer’s U.S. patent portfolio included U.S. Patent No. 6,455,574, which covered pharmaceutical compositions containing amlodipine and atorvastatin. The patent was issued in 2002 and had a listed expiration in 2020, subject to applicable patent-term adjustments and extensions. That period has passed.
The underlying single-agent patents also expired earlier:
| Drug |
Original innovator |
Principal historical patent position |
Current status |
| Amlodipine |
Pfizer |
Norvasc-related compound and formulation patents |
Expired |
| Atorvastatin |
Warner-Lambert, later Pfizer |
Lipitor-related compound and formulation patents |
Expired |
| Amlodipine/atorvastatin combination |
Pfizer |
Caduet composition and combination patents |
Expired |
Patent protection may still exist for particular manufacturing processes, crystalline forms, packaging systems, or later-developed formulations in some jurisdictions. Those rights do not recreate market exclusivity for the standard immediate-release combination tablet unless they are enforceable, commercially relevant, and difficult to design around.
When did amlodipine and atorvastatin lose exclusivity?
Amlodipine and atorvastatin are long past their primary exclusivity periods.
Atorvastatin lost U.S. market exclusivity after Lipitor generic entry beginning in late 2011. Amlodipine lost exclusivity earlier, with generic competition established in the 2000s. Caduet’s combination product retained a narrower period of protection because its fixed-dose composition was developed and patented separately, but that protection has also expired.
Exclusivity timeline
| Year |
Event |
| 1990s |
Amlodipine and atorvastatin branded products established in the U.S. |
| 2004 |
FDA approves Caduet |
| 2000s |
Generic amlodipine becomes broadly available |
| 2011 |
Generic atorvastatin enters the U.S. following Lipitor exclusivity loss |
| 2020 |
Principal Caduet combination patent term reaches expiration |
| 2020s |
Mature generic market with multiple suppliers and limited branded pricing power |
The commercial consequence is structural. Neither active ingredient can support monopoly pricing in standard oral tablets. Revenue depends on prescription volume, channel presence, contract pricing, and manufacturing cost.
How many patents currently cover the standard combination?
No active U.S. patent is expected to provide broad, enforceable exclusivity for the standard immediate-release amlodipine/atorvastatin tablet.
The relevant distinction is between:
- Broad composition patents, which have expired.
- Method-of-use patents, which could cover narrow patient populations or dosing strategies.
- Formulation patents, which could cover modified-release, multilayer, or other delivery systems.
- Process patents, which may protect manufacturing steps but usually do not prevent use of independently manufactured active ingredients.
- Foreign patents, whose scope and expiration dates vary by country.
For the conventional Caduet-type product, the first category is no longer a commercial barrier.
What formulation patents protect amlodipine and atorvastatin products?
The standard product is an immediate-release oral tablet. Its formulation technology is relatively mature, and generic manufacturers can generally reproduce the dosage form through ordinary pharmaceutical development.
Potential formulation protections may address:
- Bilayer or multilayer tablets.
- Modified-release delivery.
- Improved stability of atorvastatin.
- Particle-size control.
- Salt, polymorph, or crystalline-form selection.
- Combination tablets with specified dissolution profiles.
- Excipient systems designed to improve manufacturability or bioavailability.
These patents have limited market impact unless they protect the commercially dominant product and cannot be circumvented through a therapeutically equivalent formulation. For the ordinary amlodipine/atorvastatin tablet, the active pharmaceutical ingredients and dosage form are widely understood, lowering technical entry barriers.
Were there Paragraph IV challenges to Caduet?
Generic applicants historically used the ANDA pathway to challenge or work around Caduet patent protection. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed. Such a filing can trigger patent litigation and, in some circumstances, a 30-month stay of FDA approval.
The practical significance of any Caduet Paragraph IV challenge has declined because the relevant combination patent term has expired. New ANDA applicants generally do not face a meaningful remaining patent barrier for the standard product.
The FDA’s public Orange Book and Approved Drug Products with Therapeutic Equivalence Evaluations remain the controlling sources for current listed patents, therapeutic-equivalence codes, and approved generic products (U.S. Food and Drug Administration, n.d.-a; U.S. Food and Drug Administration, n.d.-b).
What is the generic entry risk for amlodipine and atorvastatin?
Generic entry risk is high because:
- Both active ingredients are off patent.
- The product is an immediate-release oral tablet.
- Bioequivalence is comparatively straightforward to demonstrate.
- Multiple manufacturers can source the active ingredients.
- Physician prescribing is largely generic by default.
- Substitution is supported by pharmacy and payer practices.
- No biologic manufacturing platform or cold-chain infrastructure is required.
The main barriers are commercial rather than legal. New entrants must obtain competitive manufacturing costs, maintain supply continuity, qualify for pharmacy benefit contracts, and avoid regulatory observations.
Generic launch scenarios
| Scenario |
Market effect |
| Single new entrant |
Moderate price erosion; limited share transfer |
| Several new entrants |
Rapid wholesale price compression |
| Supply disruption at incumbent suppliers |
Temporary pricing improvement for available manufacturers |
| Major payer exclusion |
Loss of volume despite regulatory approval |
| FDA manufacturing warning |
Short-term shortage risk and possible share redistribution |
| Retail demand shift toward separate tablets |
Reduced value of fixed-dose combination positioning |
Which companies compete in this market?
Competition exists at both the ingredient and combination-product levels.
Generic suppliers may include large multinational and regional manufacturers such as Viatris, Teva Pharmaceutical Industries, Sandoz, Dr. Reddy’s Laboratories, Lupin, Sun Pharmaceutical Industries, Zydus Lifesciences, Torrent Pharmaceuticals, and other approved ANDA holders. The exact supplier set varies by strength, national market, procurement contract, and time period.
The competitive landscape has three layers:
- Separate generic amlodipine and atorvastatin tablets.
- Generic fixed-dose amlodipine/atorvastatin tablets.
- Branded or specialty cardiovascular combination products with broader adherence or risk-management positioning.
The fixed-dose combination competes primarily on convenience. Separate tablets are often cheaper and allow independent titration, which can limit combination-product adoption.
How does the combination compare with separate tablets?
| Factor |
Fixed-dose combination |
Separate tablets |
| Pill burden |
Lower |
Higher |
| Dose flexibility |
Lower |
Higher |
| Manufacturing complexity |
Higher than either single agent |
Lower per product |
| Pricing power |
Limited |
Very limited |
| Adherence potential |
Better for stable regimens |
More flexible but more pills |
| Substitution risk |
High from generic combination and separate products |
High from multiple generic suppliers |
| Patent strength |
Expired |
Expired |
The combination has a clinical and commercial rationale when both therapies are required at stable doses. It is less attractive when clinicians need to adjust amlodipine and atorvastatin independently.
What is the financial trajectory for amlodipine and atorvastatin?
The financial trajectory is mature-to-declining for branded products and stable-to-volume-driven for generics.
Pfizer does not generally report Caduet revenue as a separate publicly disclosed business line. Historical Lipitor revenue was much larger than Caduet revenue, but atorvastatin revenue fell sharply after generic atorvastatin launched. The relevant financial transition was:
- High-margin branded sales before generic entry.
- Rapid price and share erosion after loss of exclusivity.
- Persistent prescription demand at substantially lower unit prices.
- Generic supplier competition based on cost and volume.
- Low growth unless supported by population expansion, cardiovascular diagnosis rates, or combination-product uptake.
Financial drivers
| Driver |
Impact |
| Generic price erosion |
Negative for revenue per tablet |
| Cardiovascular disease prevalence |
Supports unit demand |
| Aging population |
Supports chronic-treatment volume |
| Fixed-dose adherence programs |
Supports combination use |
| Pharmacy benefit negotiation |
Compresses net pricing |
| API cost and supply |
Determines manufacturer margin |
| Manufacturing quality |
Determines continuity and contract access |
| Market shortages |
Can temporarily improve pricing |
For investors, the product is unlikely to offer a credible premium-growth thesis. Its value lies in recurring demand, established clinical use, and potential operating leverage in high-volume manufacturing.
What manufacturing and intellectual-property barriers remain?
The active ingredients are commoditized, but manufacturing execution remains important.
Atorvastatin production requires control of stereochemistry, impurity profiles, particle properties, and stability. Amlodipine manufacturing requires control of active-ingredient quality, tablet uniformity, dissolution, and stability. Combination products add blend uniformity and dissolution-management requirements.
Potential barriers include:
- FDA inspection findings.
- API shortages.
- Dependence on concentrated geographic supply chains.
- Batch failures.
- Requalification after supplier changes.
- Pricing pressure that discourages redundant capacity.
- Contract-manufacturing capacity constraints.
These barriers can create temporary supply advantages but do not create durable patent exclusivity.
What litigation and settlement issues affect the market?
The principal patent-litigation window for Caduet was tied to pre-expiration ANDA challenges. That window has passed with the expiration of the key combination patent.
There is no apparent current litigation framework comparable to an active, commercially significant Paragraph IV dispute over the standard Caduet tablet. Any current dispute would more likely involve:
- Product quality or manufacturing compliance.
- Trademark or trade dress.
- Supply contracts.
- Narrow formulation or process claims.
- State pricing or competition claims involving generic supply.
Settlement agreements that delayed generic entry would have had commercial value only before the relevant patent expiration. They do not materially constrain current generic availability for the ordinary product.
What is the geographic coverage of the patent estate?
U.S. composition protection has expired. Foreign patent outcomes were not uniform because filing dates, patent-term rules, supplementary protection mechanisms, and national litigation vary.
The commercial position is broadly similar across major markets: amlodipine and atorvastatin are established generic medicines. Local market structure differs substantially, however.
| Region |
Current commercial profile |
| United States |
Mature ANDA market with extensive generic competition |
| European Union |
Mature generic market; national pricing and reimbursement rules |
| Japan |
Generic penetration governed by local approval and reimbursement practices |
| India |
Large volume market with strong domestic manufacturing presence |
| Emerging markets |
Variable generic access, pricing, and regulatory enforcement |
International manufacturers may obtain value from registrations, tender access, and local distribution even when no meaningful patent protection remains.
How strong is the patent estate for amlodipine/atorvastatin?
The patent estate is weak for the standard product and potentially stronger only for narrow improvements.
| Patent category |
Current strength |
| Active-ingredient patents |
Expired |
| Broad combination patent |
Expired |
| Standard immediate-release tablet |
Low |
| Narrow formulation claims |
Case-specific |
| Manufacturing process claims |
Case-specific |
| Method-of-use claims |
Limited and indication-specific |
| Biosimilar exclusivity |
Not applicable |
The key commercial risk is therefore generic price competition, not patent invalidity litigation.
Key Takeaways
- Amlodipine besylate and atorvastatin calcium are mature generic cardiovascular medicines.
- Caduet, Pfizer’s fixed-dose combination, was approved in 2004 under NDA 021540.
- The principal Caduet combination patent, including U.S. Patent No. 6,455,574, has expired.
- FDA exclusivity and broad Orange Book protection no longer restrict standard generic entry.
- Biosimilar competition does not apply because both ingredients are small molecules.
- Generic entry risk is high, while regulatory and manufacturing execution remain the main barriers.
- Product-specific branded revenue is not separately disclosed by Pfizer.
- The economic model is volume-based, with low unit pricing and limited long-term growth.
- Separate amlodipine and atorvastatin tablets remain the principal competitive substitute for the fixed-dose combination.
- Any remaining patent value is likely to be narrow, formulation-specific, process-specific, or jurisdiction-dependent.
FAQs
Is Caduet still patent protected?
Broad U.S. patent protection for the standard amlodipine/atorvastatin combination has expired. Narrow patents covering later formulations or manufacturing processes require separate claim-by-claim analysis.
Can a generic company launch amlodipine/atorvastatin without a Paragraph IV challenge?
Yes. If no unexpired, relevant Orange Book patent blocks approval, an ANDA applicant can rely on a certification pathway that does not require challenging an active patent.
Is amlodipine/atorvastatin a biologic or biosimilar product?
No. It is a small-molecule fixed-dose combination regulated through the ANDA generic pathway.
Why might doctors prescribe Caduet instead of separate tablets?
The combination can reduce pill burden for patients who need stable doses of both medicines. Separate tablets offer greater flexibility for dose changes and may cost less.
Can generic manufacturers still earn attractive margins on this product?
Margins can remain viable for efficient, high-volume manufacturers with reliable API sourcing and low regulatory risk. New entrants face substantial price competition and limited opportunity to sustain premium pricing.
References
-
Pfizer Inc. (2004). Caduet prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,455,574. https://patents.google.com/patent/US6455574
-
U.S. Food and Drug Administration. (n.d.-c). Abbreviated new drug application approvals. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/liaison-programs-and-resources-anda-applicants
